EP1282411A4 - Methode de traitement anticancereux - Google Patents

Methode de traitement anticancereux

Info

Publication number
EP1282411A4
EP1282411A4 EP01927380A EP01927380A EP1282411A4 EP 1282411 A4 EP1282411 A4 EP 1282411A4 EP 01927380 A EP01927380 A EP 01927380A EP 01927380 A EP01927380 A EP 01927380A EP 1282411 A4 EP1282411 A4 EP 1282411A4
Authority
EP
European Patent Office
Prior art keywords
treating cancer
cancer
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01927380A
Other languages
German (de)
English (en)
Other versions
EP1282411A1 (fr
Inventor
Thomas P Kennedy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Charlotte Mecklenburg Hospital
Original Assignee
Charlotte Mecklenburg Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charlotte Mecklenburg Hospital filed Critical Charlotte Mecklenburg Hospital
Publication of EP1282411A1 publication Critical patent/EP1282411A1/fr
Publication of EP1282411A4 publication Critical patent/EP1282411A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37Coumarins, e.g. psoralen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/452Piperidinium derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44Oxidoreductases (1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y111/00Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01Peroxidases (1.11.1)
    • C12Y111/01006Catalase (1.11.1.6)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y111/00Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01Peroxidases (1.11.1)
    • C12Y111/01009Glutathione peroxidase (1.11.1.9)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP01927380A 2000-04-26 2001-03-02 Methode de traitement anticancereux Withdrawn EP1282411A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20002800P 2000-04-26 2000-04-26
US200028P 2000-04-26
PCT/US2001/040237 WO2001080849A1 (fr) 2000-04-26 2001-03-02 Methode de traitement anticancereux

Publications (2)

Publication Number Publication Date
EP1282411A1 EP1282411A1 (fr) 2003-02-12
EP1282411A4 true EP1282411A4 (fr) 2008-05-21

Family

ID=22740013

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01927380A Withdrawn EP1282411A4 (fr) 2000-04-26 2001-03-02 Methode de traitement anticancereux

Country Status (3)

Country Link
EP (1) EP1282411A4 (fr)
AU (1) AU2001253836A1 (fr)
WO (1) WO2001080849A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10160796A1 (de) * 2001-12-11 2003-06-26 Wulf Droege Verwendung einer Cystein-haltigen Substanz zur Steigerung der Atmungsaktivität und Erythropoetin-Produktion
AU2003294668A1 (en) * 2002-09-06 2004-04-08 Institut Curie Use of inhibitors of compounds involved in the jun kinase (jnk) biochemical cellular pathway for the treatment or diagnosis of liposarcomas
DE10337638A1 (de) * 2003-08-16 2005-03-24 Kirschfeld, Kuno, Prof. Dr. Verfahren zur Behandlung der Prostatitis
US20060019907A1 (en) * 2004-07-12 2006-01-26 Research Development Foundation Guggulsterone: an inhibitor of nuclear factor - kappaB and IkappaBalpha kinase activation and uses thereof
WO2011091807A1 (fr) * 2010-01-31 2011-08-04 Abdelrahman Shata Mohammed Shata Anticoagulant et glutathion pour le traitement du cancer
WO2011135784A1 (fr) 2010-04-28 2011-11-03 株式会社Ihi Médicament traitant les tumeurs cérébrales
JP5873656B2 (ja) 2011-06-13 2016-03-01 株式会社Ihi 金属サレン錯体化合物、局所麻酔薬剤及び抗悪性腫瘍薬剤
WO2016046989A1 (fr) * 2014-09-26 2016-03-31 株式会社Ihi Agent anticancéreux et procédé de destruction de cellules cancéreuses
JP2017128552A (ja) * 2016-01-22 2017-07-27 株式会社Ihi 抗癌剤、抗癌剤の制御方法
CN112121043A (zh) * 2020-10-27 2020-12-25 澳门大学 双香豆素在抗肿瘤中的应用
CN114558122B (zh) * 2022-04-27 2023-02-21 北京肿瘤医院(北京大学肿瘤医院) 放射核素标记的过氧化氢酶及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334382A (en) * 1993-02-25 1994-08-02 Sterling Winthrop Inc. Lyophilized polyethylene oxide modified catalase composition, polypeptide complexes with cyclodextrin and treatment of diseases with the catalase compositions
US5756091A (en) * 1993-04-22 1998-05-26 Cellfire Incorporated Method of treating tumour cells using catalase

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824664A (en) * 1993-03-26 1998-10-20 U.S. Bioscience, Inc. Suppression of HIV expression by organic thiophosphate
US5922757A (en) * 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334382A (en) * 1993-02-25 1994-08-02 Sterling Winthrop Inc. Lyophilized polyethylene oxide modified catalase composition, polypeptide complexes with cyclodextrin and treatment of diseases with the catalase compositions
US5756091A (en) * 1993-04-22 1998-05-26 Cellfire Incorporated Method of treating tumour cells using catalase

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRAR SUKHDEV S ET AL: "Reactive oxygen species from NAD(P)H:quinone oxidoreductase constitutively activate NF-kappaB in malignant melanoma cells", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 280, no. 3 Part 1, March 2001 (2001-03-01), pages C659 - C676, XP002475662, ISSN: 0002-9513 *
LIU TSAN-ZON ET AL: "Differentiation status modulates transcription factor NF-kappaB activity in unstimulated human hepatocellular carcinoma cell lines", CANCER LETTERS, vol. 151, no. 1, 3 April 2000 (2000-04-03), pages 49 - 56, XP002475661, ISSN: 0304-3835 *
SCHWARTZ S A ET AL: "The role of NF-[kappa]B/I[kappa]B proteins in cancer: Implications for novel treatment strategies", SURGICAL ONCOLOGY 1999 GB, vol. 8, no. 3, 1999, pages 143 - 153, XP002475660, ISSN: 0960-7404 *
See also references of WO0180849A1 *

Also Published As

Publication number Publication date
WO2001080849A1 (fr) 2001-11-01
EP1282411A1 (fr) 2003-02-12
AU2001253836A1 (en) 2001-11-07

Similar Documents

Publication Publication Date Title
GB0014969D0 (en) Novel method of treatment
AU2003226301A8 (en) Method of treating cancer
IL213240A0 (en) Method of treatment using lighnd-immunogen conjugates
AU2003256847A8 (en) Method of treating cancer
EP1393708A4 (fr) Procede de traitement des cheveux
SI1176964T1 (sl) Uporaba et743 za zdravljenje raka
EP1320376A4 (fr) Traitement du cancer de la prostate
EP1282411A4 (fr) Methode de traitement anticancereux
GB2389532C (en) The method of treating cancer
EP1401377A4 (fr) Methodes de traitement du cancer
AU2001241779A1 (en) Method of treatment of prostate cancer
AU9402401A (en) Treatment of cancers
EP1553965A4 (fr) Methode de traitement des tumeurs
GB0008921D0 (en) Method of treatment
HK1046853A1 (zh) 治療肝癌的方法及組成物
GB0118883D0 (en) Method for treating objects
GB0026838D0 (en) Treatment method
EP1423118A4 (fr) Procede et preparation de traitement du cancer
GB0026015D0 (en) Cancer treatment
GB0122810D0 (en) Method for treating objects
GB0123897D0 (en) Method for treating objects
IL161630A0 (en) Methods of treating endometreosis
EP1303281A4 (fr) Methodes de traitement
GB0021481D0 (en) Method of treating fabric
AU2002360454A8 (en) Methods and compositions for treating cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021122

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20080423

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20080414BHEP

Ipc: A61K 45/06 20060101ALI20080414BHEP

Ipc: A61K 31/44 20060101ALI20080414BHEP

Ipc: A61K 31/66 20060101ALI20080414BHEP

Ipc: A61K 31/452 20060101ALI20080414BHEP

Ipc: A61K 31/41 20060101ALI20080414BHEP

Ipc: A61K 31/37 20060101ALI20080414BHEP

Ipc: A61K 31/366 20060101ALI20080414BHEP

Ipc: A61K 31/28 20060101ALI20080414BHEP

Ipc: A61K 31/221 20060101ALI20080414BHEP

Ipc: A61K 31/198 20060101ALI20080414BHEP

Ipc: A61K 31/122 20060101ALI20080414BHEP

Ipc: A61K 31/05 20060101AFI20011106BHEP

17Q First examination report despatched

Effective date: 20080724

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090204